AIM:

 

In view of the increasing prevalence of obesity in adolescents, the aim of this study was to determine the pharmacokinetics of the CYP3A substrate midazolam and its metabolites in overweight and obese adolescents.

 

METHODS:

 

Overweight (BMI for age ≥ 85th percentile) and obese (BMI for age ≥ 95th percentile) adolescents undergoing surgery received 2 or 3 mg intravenous midazolam as a sedative drug preoperatively. Blood samples were collected until 6 or 8 hours post dose. Population pharmacokinetic modelling and systematic covariate analysis was performed using NONMEM 7.2.

 

(후략)